A KRAS drug is likely coming — fast — as the FDA points Amgen’s frontrunner to a looming finish line

Amgen got the oncology world excited with a first look at the potential for a KRAS drug to end a decades-long roadblock in R&D. And while the field has cooled somewhat through 2020, the pharma giant now has a formal commitment from the FDA to hurry it along as researchers…

Click to view original post